Kane Biotech Expands Canadian Market Presence For Revyve™ Antimicrobial Wound Gel With Partnership

Kane Biotech Inc. has announced its step into a three-year distribution agreement with Best Buy Medical Canada for revyve™. It is an antimicrobial wound gel product. This partnership is expected to enhance the availability of the product across healthcare facilities in Canada, ensuring better access to advanced wound care solutions.

Marc Edwards, President & CEO of Kane Biotech, said in a statement, "This partnership with Best Buy Medical allows us to improve access to innovative wound care solutions for Canadians suffering from chronic, non-healing wounds. By expanding our distribution network, we are not only helping patients and healthcare providers access effective infection management and wound healing solutions, but we are also tapping into a significant financial opportunity in the Canadian wound care market."

In November 2024, Kane Biotech received Health Canada approval for revyve™ Antimicrobial Wound Gel, thus advancing its presence in the wound care market. The company has continuously laboured to bring revyve™ Antimicrobial Wound Gel into Canadian healthcare facilities by creating partnerships, developing educational content, and actively engaging healthcare providers. Kane Biotech is establishing revyve™ as a dependable infection-management substance which assists wound healing by focusing on public awareness and product availability. 

Jamie Church, CEO of Best Buy Medical, commented, "We are excited to partner with Kane Biotech to bring the revyve™ Antimicrobial Wound Gel to the Canadian market. This collaboration aligns with our mission to offer the highest quality medical products that enhance patient care and outcomes. We believe that revyve™ will be a game-changer in wound care management."